Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05109390 · ClinicalTrials.gov registry record · Phase 1
A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults
A Phase 1 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT05109390 is a Phase 1 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 72 participants.
The verdict
NCT05109390, a Phase 1 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
This was a 3-part study with each part being an open-label, fixed-sequence, 2-period study in healthy adult participants.
Interventions
- DRUG Tacrolimus
- DRUG Cyclosporine
- DRUG Danicopan
- DRUG Calcium Carbonate
- DRUG Aluminum/Magnesium Hydroxide/Simethicone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2018-07-27 |
| Est. Completion | 2018-10-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05109390
The ClinicalTrials.gov registry entry for NCT05109390 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Tacrolimus is the first listed.
NCT05109390 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05109390 about?
NCT05109390 is a clinical study titled "A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults". This was a 3-part study with each part being an open-label, fixed-sequence, 2-period study in healthy adult participants.
What is the current status of trial NCT05109390?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2018-07-27. Estimated completion is 2018-10-17.
What interventions are being tested in trial NCT05109390?
The interventions under investigation include: Tacrolimus (DRUG), Cyclosporine (DRUG), Danicopan (DRUG), Calcium Carbonate (DRUG), Aluminum/Magnesium Hydroxide/Simethicone (DRUG).
Who is sponsoring clinical trial NCT05109390?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.